Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2010 Feb;10(2):273-9. doi: 10.1517/14712590903575620.

Naptumomab estafenatox: a new immunoconjugate.

Author information

1
Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Ave, Philadelphia, PA 19111, USA.

Abstract

IMPORTANCE OF THE FIELD:

New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials.

AREAS COVERED IN THIS REVIEW:

This review examines the preclinical and the published clinical data with regards to naptumomab.

WHAT THE READER WILL GAIN:

This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent.

TAKE HOME MESSAGE:

Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.

PMID:
20053143
DOI:
10.1517/14712590903575620
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center